TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8489205

Group type: EXPERIMENTAL
Intervention: Lazabemide 100 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lazabemide 200 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lazabemide 400 mg/day
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 3446704

Group type: EXPERIMENTAL
Intervention: Gelfoam paste
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bone wax
Number of subjects: 100
Study: 29203092

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.2 mg/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.4 mg/d
Number of subjects: 225

Group type: COMPARATOR
Intervention: Fenofibrate 106.6 mg/d
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pemafibrate
Number of subjects: 225
Study: 27486235

Group type: COMPARATOR
Intervention: DHEA (800 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: DHEA (1,600 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 27
Study: 24843051

Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation catheter (PVAC)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Wide-area circumferential ablation (WACA)
Number of subjects: 188
Study: 22892814

Group type: EXPERIMENTAL
Intervention: Children <6 years old
Number of subjects: 351
Study: 20304278

Group type: EXPERIMENTAL
Intervention: TriVerse (TV) system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Molecular resonance generator (MR)
Number of subjects: 24
Study: 18272323

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic medication
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Conventional antipsychotic medication
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 82
Study: 16179200

Group type: EXPERIMENTAL
Intervention: Computerized statistical method of analyzing vessel shapes from MRA
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 64
Study: 12798469

Group type: EXPERIMENTAL
Intervention: Continuous oestradiol valerate (E(2)V) plus cyproterone acetate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cyclic E(2)V plus cyproterone acetate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Continuous combined oestrogen (E(2)) plus norethindrone acetate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: E(2) combined with local delivery of levonorgestrel
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: E(2)V plus medroxyprogesterone
Number of subjects: 149

Group type: COMPARATOR
Intervention: No HRT (reference group)
Number of subjects: 149
Study: 11005901

Group type: EXPERIMENTAL
Intervention: Direct composite restorations
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Indirect composite restorations
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Indirect inlays
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Restorations in molars
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Premolars
Number of subjects: 88
Study: 8794971

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Osseous Surgery (OS)
Number of subjects: 6
Study: 1291926

Group type: EXPERIMENTAL
Intervention: Nimesulide (1 tablet b.i.d. for 10 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diclofenac sodium (1 tablet b.i.d. for 10 days)
Number of subjects: 50
Study: 3908879

Group type: EXPERIMENTAL
Intervention: Regular exercise (endurance training), thrice weekly for one year
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study: 31988711

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 51
Study: 30001423

Group type: EXPERIMENTAL
Intervention: Home-based palliative approach (HPA)
Number of subjects: 27
Study: 26773871

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 709
Study: 24148608

Group type: EXPERIMENTAL
Intervention: Cardioembolic stroke (patients unwilling or unable to take oral anticoagulants)
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: Large artery atherothrombosis stroke
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: Small artery occlusion strokes
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: Other etiology strokes
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: Undetermined etiology strokes
Number of subjects: 1794

Group type: EXPERIMENTAL
Intervention: Index small artery occlusion stroke
Number of subjects: 1794
Study: 22045231

Group type: EXPERIMENTAL
Intervention: Laparoscopic techniques (total extraperitoneal technique, transabdominal preperitoneal technique)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional method (Prolene mesh graft technique)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgeries
Number of subjects: 75
Study: 20528002

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil-based regimen
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 18518865

Group type: EXPERIMENTAL
Intervention: Oxygen flow rate of 5 l.min(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxygen flow rate of 10 l.min(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxygen flow rate of 15 l.min(‐1)
Number of subjects: 20
Study: 15950836

Group type: EXPERIMENTAL
Intervention: Individual verbal instructions (IVI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Integrated asthma classes (AS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written information (asthma booklet, B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (including IVI, AS, and B)
Number of subjects: 60
Study: 12735671

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) plus intravenous prednisolone (1 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous prednisolone (1 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10502867

Group type: EXPERIMENTAL
Intervention: Visual motion extrapolation task implemented on the Web using Java.
Number of subjects: 0
Study: 8621369

Group type: EXPERIMENTAL
Intervention: Teaching sessions on asthma self-management principles and skills, including peak flow monitoring, conducted by school nurses for 18 children over an 8-week period.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Regular care by nurses without teaching sessions for 18 children.
Number of subjects: 36
Study: 1662978

Group type: EXPERIMENTAL
Intervention: Alkalinized local anaesthetic mixture (0.5% bupivacaine 10 ml, 2% lignocaine 10 ml with adrenaline 1 in 200,000, plus 8.4% sodium bicarbonate 2 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain local anaesthetic mixture (0.5% bupivacaine 10 ml and 2% lignocaine 10 ml with adrenaline 1 in 200,000)
Number of subjects: 0
Study: 6172942

Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.05% retinoic acid without occlusion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-HPPK patients
Number of subjects: 34
Study: 31049212

Group type: EXPERIMENTAL
Intervention: Occlusal splint and physiotherapeutic exercises
Number of subjects: 49

Group type: COMPARATOR
Intervention: Physiotherapeutic exercises only
Number of subjects: 49
Study: 29222136

Group type: EXPERIMENTAL
Intervention: Culturally tailored parenting support programme combined with the Connect parenting programme for 12 weeks (1-2 hours per week)
Number of subjects: 120
Study: 25285468

Group type: EXPERIMENTAL
Intervention: Caffeinated nitric oxide lozenge (70mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24342530

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation (EPA: 1.67 g EPA + 0.16 g DHA/d; n = 12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation (DHA: 1.55 g DHA + 0.40 g EPA/d; n = 12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: ω‐6 PUFA linoleic acid (LA: 2.2 g/d; n = 9)
Number of subjects: 33
Study: 22286020

Group type: EXPERIMENTAL
Intervention: Diacetylmorphine (DAM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 28
Study: 20024700

Group type: EXPERIMENTAL
Intervention: Polyalkylimide gel (PAIG) injections at week 0 and 6
Number of subjects: 31
Study: 17700439

Group type: EXPERIMENTAL
Intervention: Information arm (booklet providing evidence-based information on common musculoskeletal pain problems)
Number of subjects: 3808

Group type: EXPERIMENTAL
Intervention: Information and workplace screening arm
Number of subjects: 3808

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 3808
Study: 15362009

Group type: EXPERIMENTAL
Intervention: Modified fall risk factors assessment tool
Number of subjects: 82
Study: 12368394

Group type: EXPERIMENTAL
Intervention: (n-3) fatty acids (1.5 g daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10099032

Group type: EXPERIMENTAL
Intervention: Tiagabine (titrated from 8 to 48 mg/d)
Number of subjects: 12
Study: 7862924

Group type: COMPARATOR
Intervention: Nicotine gum and patch
Number of subjects: 2
Study: 2764865

Group type: EXPERIMENTAL
Intervention: Intensive treatment (16 two-hour sessions over 4 consecutive days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spaced treatment (two two-hour sessions per week for eight weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatment formats
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Generalization of treatment effects
Number of subjects: 20
Study: 324830

Group type: EXPERIMENTAL
Intervention: Anafranil
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Pertofran
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Combination of Anafranil and Pertofran
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 173
Study: 29992259

Group type: EXPERIMENTAL
Intervention: 20 Hz beta tACS with placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 Hz beta tACS with dextromethorphan
Number of subjects: 0
Study: 27939035

Group type: EXPERIMENTAL
Intervention: Early introduction of heated egg powder (50 mg/day from 6 to 9 months, 250 mg/day from 9 to 12 months)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (no egg introduction)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Early introduction of heated egg powder
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 25806626

Group type: EXPERIMENTAL
Intervention: Action Planning and Coping Planning strategies for medication adherence
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 115
Study: 24112026

Group type: EXPERIMENTAL
Intervention: milatuzumab 1.5 mg/kg, 4.0 mg/kg, 8.0 mg/kg, or 16.0 mg/kg administered twice weekly x 4
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: milatuzumab
Number of subjects: 25
Study: 21613429

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Haemoglobin
Number of subjects: 2069
Study: 19918023

Group type: EXPERIMENTAL
Intervention: Xenon-oxygen mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air-oxygen mixture (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolated CPB (pooled data from both groups)
Number of subjects: 0
Study: 17209699

Group type: EXPERIMENTAL
Intervention: Nurse case‐managed program (NCM)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Usual care program
Number of subjects: 494
Study: 15525782

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over the left posterior parietal cortex (PPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group stimulated over the visual cortex
Number of subjects: 0
Study: 11295628

Group type: COMPARATOR
Intervention: Soy protein intervention in men at high risk for recurrence, started within 4 months after surgery, followed for up to 2 years.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soy protein intervention in men with PSA failure (PSA 0.1 to 2.0 ng/mL), treatment duration of 8 months.
Number of subjects: 0
Study: 9642025

Group type: EXPERIMENTAL
Intervention: Nonfluent dysphasics reading aloud th-initial nonwords in sentential contexts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control group reading aloud th-initial nonwords in sentential contexts
Number of subjects: 0
Study: 7981558

Group type: EXPERIMENTAL
Intervention: LAD‐ORS (hydrolyzed lactalbumin with maltodextrin and sucrose)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: MS‐ORS (without hydrolyzed lactalbumin)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: G‐ORS (standard glucose ORS)
Number of subjects: 74
Study: 2645954

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA, n = 26)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Methotrexate followed by rescue with folinic acid (MTX + FA, n = 31)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Methotrexate followed by rescue with folinic acid (MTX + FA)
Number of subjects: 57
Study: 29357333

Group type: EXPERIMENTAL
Intervention: 10 mL, 40 µg/mL of O₃‐O₂
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mL, 30 µg/mL of O₃‐O₂
Number of subjects: 60
Study: 26659920

Group type: EXPERIMENTAL
Intervention: Cranio-cervical flexion training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cervical proprioception training
Number of subjects: 28
Study: 24172712

Group type: EXPERIMENTAL
Intervention: EBUS‐centred (Group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: EUS‐centred (Group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA followed by EUS‐FNA (Group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: EUS‐FNA followed by EBUS‐TBNA (Group B)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 160
Study: 24330484

Group type: EXPERIMENTAL
Intervention: Legionnaires' disease
Number of subjects: 873
Study: 20421817

Group type: EXPERIMENTAL
Intervention: Regimen A (cisplatin-vinorelbine-ifosfamide)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Regimen B (high-dose single-drug ifosfamide)
Number of subjects: 70
Study: 18387719

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 vaccine on a 0, 1, and 3 month schedule
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 vaccine on a 0, 7, and 28 day schedule
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unimmunized infectivity controls
Number of subjects: 40
Study: 16398379

Group type: EXPERIMENTAL
Intervention: 80% intraoperative oxygen
Number of subjects: 95

Group type: COMPARATOR
Intervention: 30% intraoperative oxygen
Number of subjects: 95
Study: 12025912

Group type: EXPERIMENTAL
Intervention: Oxerutins (2 g/day for grade I CVI, 3 g/day for grade II CVI in the first 2 weeks; then 1 g/day for grade I CVI, 2 g/day for grade II CVI in the following 2 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxerutins
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10428191

Group type: EXPERIMENTAL
Intervention: Risperidone (up to 2.0 mg/d) for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 21
Study: 8932560

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1680760

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Loratadine 40 mg
Number of subjects: 10
Study: 7314868

Group type: EXPERIMENTAL
Intervention: Postoperative long time anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No postoperative anticoagulation (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative long time anticoagulation in femoral reconstructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No postoperative anticoagulation in femoral reconstructions (control)
Number of subjects: 0
Study: 31325466

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF) solution
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo (tonic water)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Both SDF and placebo groups
Number of subjects: 194
Study: 27593794

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal epidural steroid injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluoroscopy-guided caudal epidural steroid injection
Number of subjects: 30
Study: 26099206

Group type: EXPERIMENTAL
Intervention: MWM and exercise/hot pack (n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: exercise/hot pack alone (n = 22)
Number of subjects: 44
Study: 24315625

Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based chemotherapy combined with taxanes
Number of subjects: 4996
Study: 21590327

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 365
Study: 18495465

Group type: EXPERIMENTAL
Intervention: Egg-based diet (12 eggs.week(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-egg diet (0 eggs.week(‐1))
Number of subjects: 12
Study: 17545758

Group type: EXPERIMENTAL
Intervention: Chemotherapy (Group 1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No chemotherapy (Group 2)
Number of subjects: 54
Study: 16359206

Group type: EXPERIMENTAL
Intervention: Fast-track recovery program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 30
Study: 12056851

Group type: EXPERIMENTAL
Intervention: Computerized WOMAC 3.0 OA Index
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paper WOMAC 3.0 OA Index
Number of subjects: 50
Study: 9856712

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Regularly administered intramuscular injections of morphine
Number of subjects: 126
Study: 7832132

Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil 1.5 mg in the left coronary artery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil 1.0 mg in the right coronary artery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil (various doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil
Number of subjects: 30
Study: 2121486

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genentech t-PA
Number of subjects: 0
Study: 7192456

Group type: EXPERIMENTAL
Intervention: Propranolol (120 to 360 mg daily, mean 198 +/- 80 mg) for 3.5 weeks to 7 months (averaging 3 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transaortal subvalvular myectomy after 1 week to 28 months (averaging 7.5 months)
Number of subjects: 20
Study: 31647854

Group type: EXPERIMENTAL
Intervention: Revefenacin for nebulization
Number of subjects: 206

Group type: COMPARATOR
Intervention: Tiotropium HandiHaler® DPI
Number of subjects: 206
Study: 30559343

Group type: EXPERIMENTAL
Intervention: Papacarie gel (caries removal with the chemical‐mechanical method)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional method (drilling)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Drill + Papacarie
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart rate, consultation duration, and number of restorations
Number of subjects: 24
Study: 26054549

Group type: EXPERIMENTAL
Intervention: Reimbursement of up to 50 US dollars for purchased vegetables (treatment group, n=69)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (n=69)
Number of subjects: 144
Study: 24365793

Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Oral NAC + i.v. saline
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: i.v. NAC + i.v. saline
Number of subjects: 307
Study: 22151564

Group type: EXPERIMENTAL
Intervention: SWIFT Cast (soft scotch ankle-foot cast)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 120
Study: 19762222

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (160/4.5 microg bid and as needed)
Number of subjects: 7855

Group type: COMPARATOR
Intervention: Conventional best practice (CBP) (ICS or ICS/LABA+/−other agents at an approved dose plus as-needed SABA)
Number of subjects: 7855
Study: 17449081

Group type: EXPERIMENTAL
Intervention: Circular patterns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random patterns
Number of subjects: 0
Study: 15513315

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 27
Study: 11401008

Group type: EXPERIMENTAL
Intervention: 20 mg EMD
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9482137

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Captopril (50 mg twice daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 69

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 69
Study: 7989400

Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone; short course; dosage not specified; duration not specified.
Number of subjects: 0
Study: 2658841

Group type: EXPERIMENTAL
Intervention: 40 mg/day Tamoxifen
Number of subjects: 34

Group type: COMPARATOR
Intervention: 20 mg/day Tamoxifen
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dose escalation to 40 mg/day after 20 mg/day
Number of subjects: 34
Study: 4157346

Group type: EXPERIMENTAL
Intervention: One daily intramuscular injection of 160 mg of gentamicin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Three injections daily (60 or 80 mg every 8 h)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: One daily injection of gentamicin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Three injections daily
Number of subjects: 21